Introduction: Clozapine is the only antipsychotic with proven superior efficacy for treatment-resistant schizophrenia. However, global utilization rates remain suboptimal due to concerns about hematological side effects. This study aimed to investigate hematological abnormalities among clozapine users at a large community center in the Brazilian countryside.
Methods: This study adopts a real-world approach and was conducted based on a retrospectively analyzed complete blood counts from clozapine users in Goiás, Brazil. We describe the total number and percentage of participants presenting blood dyscrasias. Logistic regression models, using Stata v.18, were employed to evaluate whether sex or age were associated with the presentation of neutropenia.
Results: Data from 6,160 complete blood counts from 486 patients taken between 2011 and 2018 were analyzed. Blood dyscrasias were observed in 37.4% of patients, with anemia being the most common (23.6%), followed by thrombocytopenia (9.46%) and eosinophilia (13.7%). Neutropenia occurred in 4.52% of patients, primarily mild (3.9%) and moderate (0.62%), with no cases of agranulocytosis identified.
Discussion: Clozapine users showed a higher prevalence of blood dyscrasias compared to the overall Brazilian population. Most cases of neutropenia were mild and transient. Our results suggest a lower risk of severe neutropenia and emphasize the need to investigate other blood dyscrasias.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.47626/2237-6089-2024-0967 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hematological Changes in Clozapine Users: A Study in a Brazilian Community Sample.
Trends Psychiatry Psychother
December 2024
Departamento de Psiquiatria, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, SP, Brazil. Programa de Esquizofrenia, Escola Paulista de Medicina, Universidade Federal de São Paulo (PROESQ-EPM/UNIFESP), São Paulo, SP, Brazil.
Introduction: Clozapine is the only antipsychotic with proven superior efficacy for treatment-resistant schizophrenia. However, global utilization rates remain suboptimal due to concerns about hematological side effects. This study aimed to investigate hematological abnormalities among clozapine users at a large community center in the Brazilian countryside.
View Article and Find Full Text PDFClozapine/norclozapine plasma level ratio and cognitive functioning in patients with schizophrenia spectrum disorders: a systematic review.
Ther Adv Psychopharmacol
December 2024
Department of Community Mental Health, Mental Health Service Noord-Holland Noord, Alkmaar, The Netherlands.
Background: Extant research on cognitive functioning in treatment-resistant schizophrenia (TRS) is limited and of poor quality. Cognitive impairments in patients with schizophrenia spectrum disorders (SSD) significantly influence quality of life. In patients with TRS, clozapine (CLO) is not consistently associated with improved cognitive functioning.
View Article and Find Full Text PDFRare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study.
PLoS Med
December 2024
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.
Article Synopsis
Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users.
Asian J Psychiatr
December 2024
Department of Psychiatry, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan; Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan. Electronic address:
Objectives: Second-generation antipsychotics (SGAs) are often prescribed for patients with schizophrenia; however, SGAs are associated with the risk of metabolic syndrome (MetS). This study aimed to investigate the clinical and biochemical determinants of SGA-related MetS.
Methods: Patients with schizophrenia, aged between 20 and 65 years, and under clozapine or olanzapine treatment for at least 9 months, were recruited from a mental hospital.
High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study.
Am J Psychiatry
October 2024
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (Partanen, Häppölä, Kämpe, Daly, Ripatti, Palotie, Koskela), and Faculty of Medicine (Ripatti), University of Helsinki, Helsinki; Department of Molecular Medicine and Surgery (Kämpe) and Department of Clinical Neuroscience (Tiihonen, Tanskanen, Taipale), Karolinska Institutet, Stockholm; Department of Internal Medicine (Ahola-Olli) and Department of Psychiatry (Haaki, Hietala), Turku University Hospital, Turku, Finland; Aurora Hospital, City of Helsinki, Helsinki (Hellsten); Department of Psychiatry, Faculty of Medicine and Health Technology (Rask), and Faculty of Medicine and Health Technology (Kampman), Tampere University, Tampere, Finland; Department of Psychiatry, Tampere University Hospital, Tampere, Finland (Rask); Department of Psychiatry, University of Turku, Turku, Finland (Haaki, Hietala); Department of Clinical Sciences, Psychiatry, Umeå University, Umeå, Sweden (Kampman); Department of Clinical Medicine, Psychiatry, Faculty of Medicine, University of Turku, Turku, Finland (Kampman); Department of Psychiatry, Wellbeing Services County of Ostrobothnia, Vaasa, Finland (Kampman); Department of Psychiatry, Wellbeing Services County of Pirkanmaa, Tampere, Finland (Kampman); Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tiihonen, Tanskanen, Taipale, Lähteenvuo); Center for Psychiatry Research, Stockholm City Council, Stockholm (Tiihonen); Stanley Center for Psychiatric Research (Daly, Palotie) and Program in Medical and Population Genetics (Daly, Ripatti, Palotie), Broad Institute of Harvard and MIT, Cambridge, MA; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston (Daly, Ripatti, Palotie).
Objective: The authors used longitudinal biobank data with up to 25 years of follow-up on over 2,600 clozapine users to derive reliable estimates of the real-world burden of clozapine adverse drug events (ADEs).
Methods: A total of 2,659 participants in the FinnGen biobank project had a schizophrenia diagnosis and clozapine purchases with longitudinal electronic health record follow-up for up to 25 years after clozapine initiation. Diseases and health-related events enriched during clozapine use were identified, adjusting for disease severity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!